https://www.mdanderson.org/newsroom/archived-news/erdafitinib-shows-promise-in-urothelial-cancer-patients-with-specific-mutations.h00-159224145.html
ARCHIVED: Erdafitinib shows promise in urothelial cancer patients with specific mutations | UT MD...
In an international Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR inhibitor erdafitinib...
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT03390504&r=1
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With...
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth...
a study
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-erdafitinib-locally-advanced-or-metastatic-urothelial-carcinoma
FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma | FDA
On January 19, 2024, the Food and Drug Administration approved erdafitinib (Balversa, Janssen Biotech) for locally advanced or metastatic urothelial carcinoma...
locally advancedfdaapproveserdafitinibmetastatic
https://www.jnj.com/innovativemedicine/emea/janssen-announces-erdafitinib-improved-overall-survival-versus-chemotherapy-patients-metastatic-or
Janssen Announces Erdafitinib Improved Overall Survival Versus Chemotherapy in Patients with...
overall survivalin patientsjanssenannounceserdafitinib
https://www.cancer.gov/about-cancer/treatment/drugs/erdafitinib
Erdafitinib - NCI
Erdafitinib works by blocking a protein in some cancer cells that signals the cancer cells to multiply. This may keep cancer cells from growing and may kill...
erdafitinibnci